The study team reported that children under five years with sickle cell disease in eastern Uganda scored lower on standardized developmental testing than community controls. The cohort included 350 children — 117 with SCD and 233 without — assessed at Mbale Regional Referral Hospital. The investigators used the Malawi Developmental Assessment Tool to generate development‑for‑age z‑scores (DAZ). Children with SCD had a mean DAZ deficit of 0.89 compared with peers without the condition, according to the authors. The weighted analyses produced an average exposure effect of −0.87 (95% CI −1.19 to −0.55) and an average exposure effect among the exposed of −0.62 (95% CI −1.01 to −0.23), as reported in the manuscript.
Data collection took place at the outpatient pediatric sickle cell clinic of Mbale Regional Referral Hospital between March and September 2025. The hospital serves a large catchment in the Elgon region. Children with SCD were recruited from the clinic roster; comparison children were siblings, close relatives, or neighbours within the same age range, the authors noted. Exclusion criteria included other chronic illnesses such as congenital heart disease or epilepsy. Five trained assessors administered the MDAT using Kobo Toolbox. The MDAT evaluates four domains — language, social, gross motor and fine motor — with 34 items per domain. The investigators cited validation performance for the MDAT and described assessor training before fieldwork.
Deficits occurred across all four MDAT domains. The authors documented lower scores in social, gross motor, fine motor and language domains among the SCD group versus community controls. Median child age in the sample was 40.9 months (interquartile range 27.8–54.3 months). The team emphasized that recurrent SCD complications — for example severe anemia, infections, and cerebral infarcts or silent strokes reported in the literature — represent biologically plausible mechanisms linking SCD to impaired neurodevelopment, although this particular cross‑sectional analysis does not establish causation.
The study team examined hydroxyurea exposure among children with SCD. They reported that, within the SCD subgroup, children not enrolled on hydroxyurea had lower DAZ scores in the social and language domains by 0.4 compared with those receiving hydroxyurea. The manuscript notes that hydroxyurea is recommended and supplied under Uganda clinical guidelines (2023), but that uptake and documentation vary across facilities. The authors did not provide trial‑level dosing, duration of therapy, or adherence measures in the sections included in the source text; those details were not reported in the source material provided here.
Investigators used conventional and propensity‑score informed approaches. Independent sample t‑tests compared DAZ between children with and without SCD. To adjust for measured confounding, the team applied inverse probability of treatment weighting (IPTW) to estimate the average exposure effect of SCD on neurodevelopment. The reported IPTW estimates are those cited above. The source did not list the full set of covariates included in the propensity score model within the excerpt provided, though the authors indicated collection of multiple child‑level and caregiver‑level covariates such as age, sex, nutritional status, preterm birth, immunisation history, caregiver education and household wealth.
The authors highlighted practical gaps relevant to care and interpretation. Transcranial Doppler screening for stroke risk, recommended in national guidance, was not routinely available at the study site during the data‑collection period. Hydroxyurea availability and documentation were inconsistent, the study team observed. The cross‑sectional design limits causal inference; the provided text did not include longitudinal follow‑up or data on neurodevelopmental trajectories over time. The source did not report detailed hydroxyurea dosing, duration of exposure, or adherence measures in the sections shown. These unanswered questions — implementation of routine neurodevelopmental screening, longitudinal outcomes, and the mechanisms linking SCD and domain‑specific delays in this setting — remain for future research and programmatic evaluation.
The investigators recommended integrating routine neurodevelopmental screening into SCD care to enable earlier detection and management of delays. They also signalled that efforts to improve documentation and access to recommended SCD interventions could inform whether modifying treatment or service delivery alters developmental outcomes. The manuscript ends by noting these operational gaps and the need for further data rather than proposing regulatory steps or specific trial designs.